Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Etelcalcetide

FDA-approved product (solution, intravenous), marketed as Parsabiv.

Registered studies
23
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Etelcalcetide
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Parathyroid disease
  • Secondary hyperparathyroidism

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other anti-parathyroid agents
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA50.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli33.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae15.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis46.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

23registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Etelcalcetide in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Etelcalcetide with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • MT1013 Injection for the Treatment of Secondary Hyperparathyroidism in Patients With Chronic Kidney Disease

    NCT06690242 · start 2024-11-04

    Registered record
    Registry ID
    NCT06690242
    Conditions
    Secondary Hyperparathyroidism (SHPT) in Subjects With Chronic Kidney Disease (CKD) on Hemodialysis
    Interventions
    MT1013; MT1013; Etelcalcetide Hydrochloride; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2024-11-04
    Completion
    2025-08-30
    Enrolment
    115

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSecondary Hyperparathyroidism (SHPT) in Subjects With Chronic Kidney Disease (CKD) on Hemodialysis
    InterventionMT1013; MT1013; Etelcalcetide Hydrochloride; Placebo
    PhasePhase 2
    Registry statusCompleted

  • Use of ETElcalcetidefor pReserving vitamiN K-dependent proteIn activiTY ITAlian Study

    NCT06352957 · start 2024-05-01

    Registered record
    Registry ID
    NCT06352957
    Conditions
    Hemodialysis
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Not yet recruiting
    Start
    2024-05-01
    Completion
    2027-12-31
    Enrolment
    160

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHemodialysis
    InterventionNot recorded
    PhaseNot recorded
    Registry statusNot yet recruiting

  • A Phase 3 Study of Etelcalcetide in Children With Secondary Hyperparathyroidism Receiving Hemodialysis

    NCT03969329 · start 2019-12-20

    Registered record
    Registry ID
    NCT03969329
    Conditions
    Secondary Hyperparathyroidism
    Interventions
    Etelcalcetide
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2019-12-20
    Completion
    2027-06-30
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSecondary Hyperparathyroidism
    InterventionEtelcalcetide
    PhasePhase 3
    Registry statusRecruiting

  • A Study to Investigate the Influence of PTH-lowering by Etelcalcetide (Parsabiv®) on the Calcification Propensity of Serum in Dialysis Patients

    NCT03795558 · start 2019-05-01

    Registered record
    Registry ID
    NCT03795558
    Conditions
    End Stage Renal Disease
    Interventions
    Etelcalcetide
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2019-05-01
    Completion
    2022-03-01
    Enrolment
    37

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEnd Stage Renal Disease
    InterventionEtelcalcetide
    PhasePhase 2
    Registry statusCompleted

  • A Trial of Etelcalcetide in Pediatric Participants With Secondary Hyperparathyroidism and Chronic Kidney Disease on Hemodialysis

    NCT03633708 · start 2019-04-29

    Registered record
    Registry ID
    NCT03633708
    Conditions
    Secondary Hyperparathyroidism; Chronic Kidney Disease
    Interventions
    Etelcalcetide; Standard of Care
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2019-04-29
    Completion
    2029-01-31
    Enrolment
    56

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSecondary Hyperparathyroidism; Chronic Kidney Disease
    InterventionEtelcalcetide; Standard of Care
    PhasePhase 3
    Registry statusRecruiting

  • The Effect of Etelcalcetide on CKD-MBD

    NCT03960437 · start 2018-09-06

    Registered record
    Registry ID
    NCT03960437
    Conditions
    Chronic Kidney Disease Mineral and Bone Disorder; Renal Osteodystrophy; Vascular Calcification; Hyperparathyroidism; Secondary, Renal
    Interventions
    Etelcalcetide
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2018-09-06
    Completion
    2020-11-19
    Enrolment
    22

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Kidney Disease Mineral and Bone Disorder; Renal Osteodystrophy; Vascular Calcification; Hyperparathyroidism +1 more
    InterventionEtelcalcetide
    PhasePhase 2
    Registry statusCompleted

  • Head-to-Head Study of Etelcalcetide and Cinacalcet in Asian Hemodialysis Patients With Secondary Hyperparathyroidism (SHPT)

    NCT03299244 · start 2018-05-15

    Registered record
    Registry ID
    NCT03299244
    Conditions
    Secondary Hyperparathyroidism; Chronic Kidney Disease
    Interventions
    Etelcalcetide; Cinacalcet
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2018-05-15
    Completion
    2020-04-08
    Enrolment
    637

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSecondary Hyperparathyroidism; Chronic Kidney Disease
    InterventionEtelcalcetide; Cinacalcet
    PhasePhase 3
    Registry statusCompleted

  • Effect of Active Vitamin D and Etelcalcetide on Human Osteoclasts in Patients With Chronic Kidney Disease

    NCT03527511 · start 2018-05-14

    Registered record
    Registry ID
    NCT03527511
    Conditions
    Bone Disorder; Chronic Kidney Diseases
    Interventions
    Measure of etecalcetide on osteoclastic biology
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2018-05-14
    Completion
    2018-10-22
    Enrolment
    21

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBone Disorder; Chronic Kidney Diseases
    InterventionMeasure of etecalcetide on osteoclastic biology
    PhaseNot recorded
    Registry statusCompleted

  • A Phase 1 Study to Evaluate PK, Safety and Tolerability of AMG 416

    NCT03283098 · start 2018-03-01

    Registered record
    Registry ID
    NCT03283098
    Conditions
    Secondary Hyperparathyroidism
    Interventions
    Etelcalcetide; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2018-03-01
    Completion
    2019-02-04
    Enrolment
    33

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSecondary Hyperparathyroidism
    InterventionEtelcalcetide; Placebo
    PhasePhase 1
    Registry statusCompleted

  • Effect of Etelcalcetide on Cardiac Hypertrophy in Hemodialysis Patients

    NCT03182699 · start 2017-10-01

    Registered record
    Registry ID
    NCT03182699
    Conditions
    Secondary Hyperparathyroidism; Chronic Kidney Disease Requiring Chronic Dialysis; Left Ventricular Hypertrophy
    Interventions
    cardiac MRI; echocardiography with strain; Laboratory tests; Body composition monitoring; lung ultrasound
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2017-10-01
    Completion
    2019-12-20
    Enrolment
    62

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSecondary Hyperparathyroidism; Chronic Kidney Disease Requiring Chronic Dialysis; Left Ventricular Hypertrophy
    Interventioncardiac MRI; echocardiography with strain; Laboratory tests; Body composition monitoring +1 more
    PhasePhase 4
    Registry statusCompleted

  • A Single-dose Study in Paediatric Patients Aged 2 to Less Than 18 Years With Secondary Hyperparathyroidism (sHPT) Receiving Haemodialysis

    NCT02833857 · start 2017-03-14

    Registered record
    Registry ID
    NCT02833857
    Conditions
    Chronic Kidney Disease, Secondary Hyperparathyroidism
    Interventions
    Etelcalcetide
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2017-03-14
    Completion
    2018-10-31
    Enrolment
    11

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Kidney Disease, Secondary Hyperparathyroidism
    InterventionEtelcalcetide
    PhasePhase 1
    Registry statusCompleted

  • Extension Study of Etelcalcetide for Treatment of Secondary Hyperparathyroidism in Patients With Chronic Kidney Disease on Hemodialysis

    NCT02102204 · start 2014-03-25

    Registered record
    Registry ID
    NCT02102204
    Conditions
    Hyperparathyroidism, Secondary
    Interventions
    Etelcalcetide
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2014-03-25
    Completion
    2017-06-26
    Enrolment
    902

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHyperparathyroidism, Secondary
    InterventionEtelcalcetide
    PhasePhase 3
    Registry statusCompleted

  • Pharmacokinetics and Excretion of [¹⁴C]Etelcalcetide (AMG 416) in Patients With End Stage Renal Disease (ESRD) Receiving Dialysis

    NCT02054572 · start 2014-02-07

    Registered record
    Registry ID
    NCT02054572
    Conditions
    Secondary Hyperparathyroidism in Patients With ESRD on Hemodialysis
    Interventions
    [¹⁴C]Etelcalcetide
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2014-02-07
    Completion
    2014-08-15
    Enrolment
    6

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSecondary Hyperparathyroidism in Patients With ESRD on Hemodialysis
    Intervention[¹⁴C]Etelcalcetide
    PhasePhase 1
    Registry statusCompleted

  • Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet

    NCT01896232 · start 2013-08-13

    Registered record
    Registry ID
    NCT01896232
    Conditions
    Secondary Hyperparathyroidism; Chronic Kidney Disease
    Interventions
    Etelcalcetide; Cinacalcet; Oral Placebo; Intravenous Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2013-08-13
    Completion
    2015-01-08
    Enrolment
    683

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSecondary Hyperparathyroidism; Chronic Kidney Disease
    InterventionEtelcalcetide; Cinacalcet; Oral Placebo; Intravenous Placebo
    PhasePhase 3
    Registry statusCompleted

  • Study to Assess the Impact on Calcium Levels When Hemodialysis Patients With Secondary Hyperparathyroidism (SHPT) Switch From Cinacalcet to Etelcalcetide

    NCT01932970 · start 2013-08-12

    Registered record
    Registry ID
    NCT01932970
    Conditions
    Hyperparathyroidism, Secondary
    Interventions
    Etelcalcetide
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2013-08-12
    Completion
    2017-02-14
    Enrolment
    158

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHyperparathyroidism, Secondary
    InterventionEtelcalcetide
    PhasePhase 3
    Registry statusCompleted